Submitted by Anonymous (not verified) on 30 October 2023 - 7:50
Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Multiple Sclerosis, Date of authorisation: 12/09/2013, Revision: 22, Status: Authorised
Source: